A New York federal court has reinstated the lead plaintiff selection process in the securities class action lawsuit against Spectrum Pharmaceuticals (SPPI). The court’s decision follows the August 4, 2025, disqualification of the previously appointed lead plaintiff. The new deadline for investors to apply is September 24, 2025.
The lawsuit, Christiansen v. Spectrum Pharmaceuticals, Inc., et al., alleges that Spectrum misled investors regarding its drug, poziotinib, intended for non-small cell lung cancer treatment. The complaint claims the company made inaccurate statements about the drug’s safety and efficacy.
Specifically, the company allegedly failed to disclose the lack of patient enrollment in a mandatory Phase 3 clinical trial. This information came to light in September 2022 when an FDA advisory committee report revealed negative data, leading to a significant drop in Spectrum‘s stock price.
Hagens Berman, a national shareholder rights firm, is actively investigating these claims. The firm is urging investors who experienced substantial losses during the class period—March 17, 2022, to September 22, 2022—to consider becoming the lead plaintiff. This role involves overseeing the litigation and representing the interests of all class members.
Hagens Berman is encouraging individuals with non-public information related to Spectrum to come forward. The firm highlighted the SEC Whistleblower program, which offers rewards of up to 30 percent of any successful recovery.
Hagens Berman is a global plaintiffs’ rights firm specializing in complex litigation focused on corporate accountability. The firm has a history of representing investors, whistleblowers, and others in cases involving corporate negligence. They report having secured over $2.9 billion in settlements.
Investors seeking further information about the Spectrum Pharmaceuticals case and the lead plaintiff application process are encouraged to contact Hagens Berman directly. The firm provided contact details for inquiries.
Related
